Antiarrhythmic drugs: mechanisms of action, clinical effects, indications for use

Article Sidebar

PDF (Russian)
Published: Jun 14, 2019
DOI: https://doi.org/10.31928/1608-635X-2019.2.7690
How to Cite
“Antiarrhythmic Drugs: Mechanisms of Action, Clinical Effects, Indications for Use”. Ukrainian Journal of Cardiology, vol. 26, no. 2, June 2019, p. 76-90, https://doi.org/10.31928/1608-635X-2019.2.7690.
Issue
Vol. 26 No. 2 (2019): Ukrainian Journal of Cardiology
Section
Lectures

Main Article Content

G. M. Solovyan
National Scientific Center «M.D. Strazhesko Institute of Cardiology» of NAMS of Ukraine, Kyiv, Ukraine
T. V. Mikhalieva
National Scientific Center «M.D. Strazhesko Institute of Cardiology» of NAMS of Ukraine, Kyiv, Ukraine

Abstract

The lecture is devoted to one of the most difficult problems of modern cardiology – the use of antiarrhythmic therapy in clinical practice. The basic mechanisms of arrhythmias, aspects of their onset, maintenance and termination are briefly described. The current evidence on the electrophysiological mechanisms of cardiac arrhythmias – re-entry, abnormal impulse formation, and trigger activity – is presented. The article contains information about the remodeling of ion channels properties. The Sicilian gambit is analyzed, in which the mechanisms of arrhythmias are compared to the mechanisms of anti-arrhythmic action of drugs. Classification of anti-arrhythmic drugs, their mechanisms of action, indications and contraindications, side effects, and interaction with other drugs are presented.

Article Details

Keywords:

arrhythmia, potential of action, ion channels, drug, mechanisms of action, therapy

References

Ardashev VN, Ardashev VA, Steklov VІ. Treatment of heart rhythm disturbances. M.: ID MEDPRAKTIKA, 2005.228 p. (in Russ.).

Denysiuk VI, Dziak GV, Moroz VM. Treatment of arrhythmias: ways to improve the effectiveness and safety of antiarrhythmic drugs. Vynnytsa: GP GKF, 2005.640 p. (in Russ.).

Kushakovskii MS, Grishkin YN. Heart arrhythmias. Cardiac rhythm disorders and conduction impairment. Manual for doctors . SPb.: “Foliant”, 2014.720 p. (in Russ.).

Kovalenko VN, Sychev OS. Heart rhythm and conduction disorders. A guide for doctors. Kiev, 2009.654 p. (in Russ.).

Nedostup AV. Some difficulties and controversial issues of arrhythmia. Kardiologiia i serdechno-sosudistaia khirurgiia [Cardiology and cardiovascular surgery] 2007;1:9–15. (in Russ.).

Preobrazhenskii DV, Marenych AV, Andreichenko TA, Kyktev VH, Sydorenko BA. Propaphenon: clinical pharmacology and efficiency in supraventricular tachyarrhythmias. Ross. kardyol. Zhurn. [ Russian Journal of Cardiology]. 2001;4:93–98. (in Russ.).

Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nicolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Arytmolohiia [Arytmology] 2016;18(2):5–36 (in Ukr.) https://doi.org/10.1093/eurheartj/ehv316.

Chazov EI, Golitcyn SP. Guide to heart rhythm disturbances. M.: GEOTAR-Media, 2010.416 p. (in Russ.).

Fohoros RM. Antiarrhythmic drugs. Moscow: SPb,1999.190 p. (in Russ.).

Fomyna YH, Vetluzhskyi AV, Tarzymanova AY, Abramova AA. Efficacy and safety of propafenone in restoring and maintaining sinus rhythm in patients with recurrent atrial fibrillation - results of an open placebo-controlled study. Kardyovask. ter. y profyl. [Cardiovascular therapy and prevention]. 2005;2:67–73. (in Russ.).

A comparison of rate control and rhythm control in patients with atrial fibrillation / The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. N Engl J Med 2002;347:1825–1833. https://doi.org/10.1056/NEJMoa021328.

Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, Gaggiol G. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in the-pocket” approach. N Engl J Med 2004;351:2384–2391. https://doi.org/10.1056/NEJMoa041233.

Al-Khatib SM, Allen LaPointe NPJ, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Rovsic TJ, Raju SS, Shan B, Kosinski AS, McBrogm AJ, Sanders GD. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Inter Med 2014;160:760–773. https://doi.org/10.7326/M13-1467.

Allessie M.A. Atrial re-entry / Allessie M.A., Bonke F.I., Kirhhof C.J. Cardiac Electrophysiology. Textbook / M. Rosem, M.J. Janse, A.L. Wit (eds). – Mount Kisco, NY: Futura Publishing Company INC., 1990.555–571.

Andersen S, Hansen M, Gislason G, Schramm T, Folke F, Fosbøl E , Abildstrøm SZ, Madsen M, Køber L, Torp-Pedersen C. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace 2009;11:886–891. https://doi.org/10.1093/europace/eup119.

Andrikopoulos G, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Сardiol 2015;7:76–85. https://doi.org/10.4330/wjc.v7.i2.76.

Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313–321. https://doi.org/10.1016/j.jacc.2010.07.046.

Camm A, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–2747. https://doi.org/10.1093/eurheartj/ehs253.

Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class Ic drugs for cardiversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003;41:255–262. DOI: https://doi.org/10.1016/S0735-1097(02)02705-5.

Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, van Gelder I, Gorenek B, Kaski JC, Kjeldsen K, Lip GYH, Merkely B, Okumura K, Piccini JP, Potpara T, Poulsen BK, Saba M, Savelieva I, Tamargo JL, Wolpert C. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace 2018;20:731–732an. https://doi.org/10.1093/europace/eux373.

Effect of antiarrhythmic agents moricizine on survival after myocardial infarction / The Cardiac Arrhythmia Suppression Trial II investigators. N Engl Med 1992;327:227–233. https://doi.org/10.1056/NEJM199207233270403.

Issa Z. Clinical Arrhythmology and Electrophysiology: A Comparison to Braunwaldʼs Heart Disease / Issa Z, Miller J, Zipes D. Saunders, 2012.744 p.

Iwai T, Tanonaka K, Inoue R, Kasahara S, Motegi K, Nagaya S, Takeo S.R. Sodium accumulation during ischemia induces mitochondrial damage in perfused rat hearts. Cardiovasc Res 2002;55:141–149. DOI: https://doi.org/10.1016/S0008-6363(02)00282-1.

Hohnloser S, Zabel M. Shot- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;70:3A-9A; discussion 9A-10A. DOI: https://doi.org/10.1016/0002-9149(92)91071-B.

Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, Steinbeck G, Treszi A, Wegscheider K, Breithardt G. Shot-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomized, open-tabel, binded endpoint assessment trial. Lancet 2012;380:238–246. https://doi.org/10.1016/S0140-6736(12)60570-4.

Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652–659. https://doi.org/10.1161/CIRCEP.109.870204.

Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, DʼAgostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–1046. https://doi.org/10.1161/01.CIR.0000140263.20897.42.

McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, Robinson KA, Powe NR. Management of new onset atrial fibrillation (evidence report/Technology assessment). In: Agency for Healthcare Research and Quality. 2001, Publication No. AHRQ 01-E026.

Nguyen T, Hilmer S, Cumming R. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol 2013;167:2412–2420. https://doi.org/10.1016/j.ijcard.2013.01.184.

Pott C, Dechering D, Reinke F, Muszynski A, Zellerhoff S, Bittner A, Köbe J, Wasmer K, Schulze-Bahr E, Mönnig G, Kotthoff S, Eckardt L. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. Europace 2011;13:897–901. https://doi.org/10.1093/europace/euq517.

Preliminary report: effect of encainide and flecainide on mortality in randomized trial of arrhythmia suppression after myocardial infarction / The Cardiac Arrhythmia Supression Trial investigators. N Engl Med 1989;321:406–412. https://doi.org/10.1056/NEJM198908103210629.

Pritchett E, Wilkinson W. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991;67:976–980. DOI: https://doi.org/10.1016/0002-9149(91)90170-P.

Reiffel J.A. Propafenone / Reiffel J.A., Murray K.T., Prystovsky E.N. Cardiovascular drug therapy / F.M. Messerly (ed). Philadelphia, 1996.1349–1360.

Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913–920. https://doi.org/10.1056/NEJM200003303421302.

Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Prichett EL, Camm AJ. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518–1525. https://doi.org/10.1161/CIRCULATIONAHA.107.723866.

Schwartz PJ, Zaza A. The Sicilian Gambit revisited, theory and practice. Eur Heart J 1992; 13:23F-29F. DOI: https://doi.org/10.1093/eurheartj/13.suppl_F.23.

Singh B.N. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. Eur Heart J 1993;14(suppl. H):14–23. DOI: https://doi.org/10.1093/eurheartj/14.suppl_H.14.

Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD, Ezekowitz MD. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861–1872. https://doi.org/10.1056/NEJMoa041705.

Vaughan Williams EM. Classifying anthiarrhythmic actions: by facts or speculation. J Clin. Pharmacol. 1992;32:964–977. DOI: https://doi.org/10.1002/j.1552-4604.1992.tb03797.x.

Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213–220. https://doi.org/10.2147/CLEP.S47385.